Document is current
Any future updates will be listed below
-
Authors
Nakajima, Kenichi https://orcid.org/0000-0001-7188-8746
Komatsu, Junji
Matsumura, Takeshi
Orimo, Satoshi
Yoshita, Mitsuhiro
Frantellizzi, Viviana
De Feo, Maria Silvia
Greenfinch, Gemma
Thomas, Alan
Assante, Roberta
Acampa, Wanda
Shirasaki, Naoki
Yokoyama, Kunihiko
Wakabayashi, Hiroshi
Noguchi-Shinohara, Moeko
Ono, Kenjiro
Kinuya, Seigo
-
Funding
Funding for this research was provided by:
Kanazawa University
- License Information
-
More Information
Article History
Received: 3 October 2025
Accepted: 25 November 2025
First Online: 14 January 2026
Declarations
:
: All methods were applied according to the ethical standards enshrined in the Declaration of Helsinki (2013 amendment) or comparable ethical standards. The Ethics Committee at Kanazawa University approved this retrospective study (Approval no: 2024 − 143, 114645) Participation in this multicenter study was approved by the ethics committees at each institution or followed comparable guidelines.
: The Ethics Committee at Kanazawa University waived the need for patients to provide written, informed consent to participate as the study investigated innominate data.
: K. Nakajima belonged to a department endowed by PDRadiopharma (Tokyo, Japan), Nihon Medi-Physics (Tokyo, Japan), and Siemens Healthcare Japan (Tokyo, Japan), and has a collaborative research agreement with PDRadiopharma, Inc. (Tokyo, Japan), which markets 123 I- m IBG (myoMIBG™) in Japan.
